Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.…
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
Alvotech (NASDAQ: ALVO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,279 employees.
The shares were at 4.120 USD on 20 November 2026, down 26.4% over 52 weeks. Its 52-week range is 2.940 USD to 6.530 USD: the price is 36.9% below the high and 40.1% above the low.
Its market capitalisation is 1.47B USD.
Alvotech reports return on equity of -9.8%, an operating margin of 12.9% and revenue down 2.0% year over year.
Its debt exceeds its cash by 1.50B USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 7.500 USD is 82.0% above the current price. The next earnings report is expected on 10 March 2027.